Saturday 17 October 2026
Export MREO’s income statement to Excel — free account
Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
0.30
0.01
−3.23%
Follow MREO
| Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
Altman Z-Score |
— | — | — | (0.80) | — | 2.34 | — | (9.11) |
P/S ratio |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
P/FCF ratio |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (1.86) | — | (14.76) | — | (27.03) |
P/Operating CF |
— | — | — | 0.00 | — | (44.68) | — | (8.72) |
P/B ratio |
— | — | — | 0.00 | — | 6.00 | — | 1.64 |
Price to Tangible BV |
— | — | — | 0.00 | — | 6.13 | — | 1.66 |
EV/Sales |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
EV/EBITDA |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
EV/Operating CF |
— | — | — | 2.14 | — | (12.09) | — | (0.99) |
EV/FCF |
— | — | — | 2.11 | — | (11.45) | — | (0.98) |
Quick Ratio |
1.74 | 0.60 | 2.95 | 7.70 | 2.80 | 6.05 | 5.04 | 9.53 |
Current Ratio |
2.13 | 1.02 | 3.47 | 7.92 | 3.09 | 6.72 | 5.40 | 10.46 |
Net Debt/EBITDA |
0.17 | (0.11) | 0.20 | 3.94 | 1.26 | 1.90 | 1.49 | 1.04 |
Debt/Assets |
31.93% | 23.73% | 25.64% | 11.38% | 0.00% | 6.61% | 0.00% | 0.00% |
Debt/Equity |
0.66 | 0.51 | (1.08) | 0.16 | 0.00 | 0.09 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.39 | 0.00 | 0.14 | 0.00 | 0.01 |
Operating CF/Net income |
0.72 | 1.32 | 0.17 | (0.41) | 1.16 | 0.72 | 0.76 | 0.74 |
Capex/Depreciation |
(0.88) | (0.01) | 1.13 | (0.66) | (0.07) | (0.74) | (1.20) | (0.51) |
Interest Coverage |
(14.91) | (11.30) | (5.89) | (5.21) | (13.04) | (9.86) | (34.57) | (157.28) |
| 0.00% | (93.52%) | (1,305.77%) | 34.38% | (48.98%) | (57.81%) | (77.58%) | (82.21%) | |
| 0.00% | (44.45%) | (219.76%) | 13.74% | (33.61%) | (40.95%) | (60.54%) | (68.48%) | |
ROIC |
(82.38%) | (55.60%) | 0.00% | (161.74%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(173.44%) | (287.61%) | (719.75%) | 14.25% | (82.18%) | (53.89%) | (70.71%) | (102.50%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 22.30 | — | 0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 64.61% | 0.00% | 174.18% | 0.00% | 3,553.20% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 43.70% | 0.00% | 184.24% | 0.00% | 4,601.60% |
Intangible Assets out of Total Assets |
0.49 | 0.51 | 0.50 | 0.19 | 0.00 | 0.02 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 9.06% | 0.00% | 49.24% | 0.00% | 1,519.60% |
Graham Net Nets |
— | — | — | 0.00 | — | 0.16 | — | 0.60 |
Graham Number |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
Earnings Yield |
— | — | — | (8.02%) | — | (8.02%) | — | (62.55%) |
Free Cash Flow Yield |
— | — | — | 0.00% | — | (7.36%) | — | (46.73%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.48 | 0.00 | 0.08 | 0.00 | 0.00 |
Operating CF per Share |
(2.17) | (3.28) | (0.54) | (0.07) | (0.40) | (0.16) | (0.22) | (0.19) |
Capex per Share |
0.00 | 0.00 | 0.03 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(2.17) | (3.28) | (0.50) | (0.07) | (0.40) | (0.16) | (0.23) | (0.20) |
Cash per Share |
2.58 | 1.17 | 0.44 | 1.23 | 0.57 | 0.44 | 0.47 | 0.26 |
Shareholders Equity per Share |
3.07 | 2.87 | (0.28) | 1.15 | 0.43 | 0.38 | 0.41 | 0.26 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.07 | 2.87 | (0.28) | 1.15 | 0.43 | 0.38 | 0.41 | 0.26 |
Free Cash Flow |
(30.93) | (58.68) | (34.07) | (7.78) | (48.83) | (21.55) | (33.53) | (31.29) |
Working Capital |
24.45 | 0.71 | 27.17 | 119.33 | 50.82 | 54.27 | 60.92 | 40.72 |
Capital Expenditures |
(0.04) | (0.03) | 2.32 | (0.58) | (0.01) | (0.42) | (0.70) | (0.32) |
Net Current Asset Value |
(0.01) | (20.12) | (61.88) | 83.75 | 49.19 | 47.80 | 59.34 | 40.02 |
EV/EBIT |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.04 | 0.00 | 0.64 |
Price to Operating Income |
— | — | — | 0.00 | — | 0.00 | — | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.25 | 0.14 | 1.02 | 0.25 | 0.33 | 1.40 | 2.26 | 4.54 |
Cash ROIC |
(28.33%) | (59.59%) | (107.69%) | (2.88%) | (40.84%) | (19.18%) | (25.64%) | (38.20%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 18.57 | — | 0.00 | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 6.38 | (0.33) | 0.88 | 0.00 | 0.07 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 50.93 | (1,112.20) | 332.67 | 0.00 | 3,658.23 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 |
Average Receivables |
— | 1.40 | 2.16 | 2.70 | — | — | — | — |
Average Payables |
— | 7.11 | 6.20 | 3.86 | 3.46 | 2.92 | 2.39 | 1.89 |
Average Assets |
— | 100.09 | 95.61 | 127.33 | 125.62 | 71.96 | 71.44 | 61.15 |
Average Common Equity |
— | 47.57 | 16.09 | 50.89 | 86.21 | 50.97 | 55.75 | 50.94 |
Columns are period end dates